Stockscreener 앱 받기
9.90
0.90%
-0.09
시간 외 거래:
9.90
전일 마감가:
$9.99
열려 있는:
$9.96
하루 거래량:
342.99K
Relative Volume:
1.43
시가총액:
$489.76M
수익:
$62.02M
순이익/손실:
$-45.65M
주가수익비율:
-10.76
EPS:
-0.92
순현금흐름:
$-9.60M
1주 성능:
-4.72%
1개월 성능:
+18.99%
6개월 성능:
+10.74%
1년 성능:
+4.32%
1일 변동 폭
$9.64
$10.04
1주일 범위
$9.64
$10.55
52주 변동 폭
$7.44
$10.90
Theravance Biopharma Inc Stock (TBPH) Company Profile
명칭
Theravance Biopharma Inc
전화
650-808-6000
주소
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
TBPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
9.90 | 489.76M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | 개시 | BTIG Research | Buy |
| 2024-01-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-15 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-08-25 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 개시 | JP Morgan | Overweight |
| 2020-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 개시 | Cowen | Outperform |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-06 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 개시 | H.C. Wainwright | Buy |
| 2018-03-29 | 재개 | Piper Jaffray | Overweight |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-12-21 | 개시 | Needham | Buy |
| 2016-11-03 | 개시 | Piper Jaffray | Overweight |
| 2016-10-12 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 개시 | Guggenheim | Buy |
| 2016-06-20 | 재확인 | Leerink Partners | Outperform |
| 2016-05-12 | 개시 | Leerink Partners | Outperform |
| 2016-05-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
모두보기
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecast By Investing.com - Investing.com India
Theravance Biopharma (TBPH) Reports Q1 Revenue and Strategic Progress | TBPH Stock News - GuruFocus
Theravance Biopharma Inc Surpasses Revenue Estimates with $58.3 Million in Q1 2025, Highlighting Strong Market Performance - GuruFocus
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Purchased by Barclays PLC - Defense World
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Theravance Biopharma Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
(TBPH) Investment Report - news.stocktradersdaily.com
Invesco Ltd. Has $433,000 Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Legal & General Group Plc Reduces Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
BTIG lifts Theravance Biopharma stock target to $24 on TRELEGY sales - Investing.com
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress - PR Newswire
New Phase 3 Analysis Reveals Ampreloxetine Impact on MSA Patients with Orthostatic Hypotension - Stock Titan
Zacks Research Issues Positive Outlook for TBPH Earnings - Defense World
Rep. George Whitesides Sells Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock - Defense World
Geode Capital Management LLC Increases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
JPMorgan Chase & Co. Reduces Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Russell Investments Group Ltd. Lowers Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma to Report First Quarter 2025 Financial Resu - GuruFocus
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 | TBPH Stock News - GuruFocus
Theravance Biopharma Sets Q1 2025 Earnings Date: Key Financial Results Coming May 8 - Stock Titan
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Alliancebernstein L.P. - Defense World
(TBPH) Trading Signals - news.stocktradersdaily.com
Vanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Position Trimmed by Corebridge Financial Inc. - Defense World
Wellington Management Group LLP Raises Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
KLP Kapitalforvaltning AS Acquires New Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
American Century Companies Inc. Acquires 8,289 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma at Jones Conference: Strategic Growth and Future Prospects - Investing.com Canada
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire
Teacher Retirement System of Texas Takes $103,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares - MSN
Theravance Biopharma to Participate in an Upcoming Investor Conference - Longview News-Journal
Exclusive Access: Theravance Biopharma Leadership Reveals Strategy at Jones Healthcare Conference - Stock Titan
Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Yahoo Finance
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PR Newswire
Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from Brokerages - Defense World
Q1 EPS Forecast for Theravance Biopharma Reduced by Analyst - Defense World
(TBPH) Investment Analysis - news.stocktradersdaily.com
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next? - Defense World
Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha
Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Theravance Biopharma, Inc. to Host Earnings Call - ACCESS Newswire
Zacks Research Brokers Lower Earnings Estimates for TBPH - Armenian Reporter
What is Zacks Research’s Forecast for TBPH Q1 Earnings? - Defense World
Where are the Opportunities in (TBPH) - news.stocktradersdaily.com
Equities Analysts Issue Forecasts for TBPH FY2028 Earnings - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Theravance Biopharma Inc (TBPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.73%
1.07%
자본화:
|
볼륨(24시간):